CN1640392A - 大剂量的羟基红花黄色素a或其可药用盐在缺血引起的急性脑中风的药物中的应用 - Google Patents
大剂量的羟基红花黄色素a或其可药用盐在缺血引起的急性脑中风的药物中的应用 Download PDFInfo
- Publication number
- CN1640392A CN1640392A CN 200410023508 CN200410023508A CN1640392A CN 1640392 A CN1640392 A CN 1640392A CN 200410023508 CN200410023508 CN 200410023508 CN 200410023508 A CN200410023508 A CN 200410023508A CN 1640392 A CN1640392 A CN 1640392A
- Authority
- CN
- China
- Prior art keywords
- administration
- hydroxysafflor yellow
- dose
- dosage
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 208000006011 Stroke Diseases 0.000 title claims abstract description 12
- 150000003839 salts Chemical class 0.000 title claims abstract description 12
- 206010008190 Cerebrovascular accident Diseases 0.000 title abstract description 6
- 230000002490 cerebral effect Effects 0.000 title abstract description 5
- 230000000302 ischemic effect Effects 0.000 title description 12
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 claims abstract description 10
- 230000001154 acute effect Effects 0.000 claims abstract description 9
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 claims description 59
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 claims description 58
- 208000028867 ischemia Diseases 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 10
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 9
- 206010008118 cerebral infarction Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 5
- -1 hydroxy carthamus Chemical compound 0.000 abstract description 2
- 241000208809 Carthamus Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 206010053567 Coagulopathies Diseases 0.000 description 15
- 230000035602 clotting Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 206010028851 Necrosis Diseases 0.000 description 11
- 230000017074 necrotic cell death Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000000269 carotid artery external Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 208000005189 Embolism Diseases 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 208000001435 Thromboembolism Diseases 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 206010000117 Abnormal behaviour Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003194 forelimb Anatomy 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- HUGRHFXHKFEGEY-UHFFFAOYSA-K trisodium 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid trichloride Chemical compound [Na+].[Na+].[Na+].[Cl-].[Cl-].[Cl-].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HUGRHFXHKFEGEY-UHFFFAOYSA-K 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 241000195622 Astasia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
剂量 | 不同时间(h)给药组的缺血坏死面积(%) | ||||
0.5 | 1 | 3 | 6 | 10 | |
1 | 20.0±6.4 | 22.4±6.5 | 23.2±5.6 | 23.3±6.7 | 22.8±7.1 |
6 | 18.1±4.0* | 19.0±4.2* | 21.1±6.4 | 22.4±6.5 | 22.9±5.9 |
8 | 17.8±3.2** | 17.9±3.4** | 18.2±3.0** | 20.0±6.9 | 20.0±6.9 |
16 | 17.4±3.0* * | 17.7±2.9** | 18.4±3.2** | 18.8±2.2** | 21.1±6.5 |
32 | 17.7±3.6** | 17.8±3.3** | 17.8±3.5** | 18.5±3.0** | 19.8±3.9* |
行为障碍 | 缺血面积(%) | |
假手术组 | 0 | 0 |
模型对照组 | 9.2±1.1 | 24.4±4.5 |
Nim组 | 5.4±2.5** | 18.8±3.4** |
HSYA 8mg/kg 3h尾静脉给药 | 6.7±1.3** | 18.1±3.8** |
HSYA 8mg/kg 3h灌服给药 | 8.7±1.4* | 22.8±3.7* |
HSYA 32mg/kg 10h尾静脉给药 | 6.0±1.2** | 17.6±3.5** |
HSYA 32mg/kg 10h灌服给药 | 8.6±1.7* | 23.4±3.0* |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410023508XA CN100418522C (zh) | 2004-01-08 | 2004-01-08 | 大剂量的羟基红花黄色素a或其可药用盐的制药应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410023508XA CN100418522C (zh) | 2004-01-08 | 2004-01-08 | 大剂量的羟基红花黄色素a或其可药用盐的制药应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1640392A true CN1640392A (zh) | 2005-07-20 |
CN100418522C CN100418522C (zh) | 2008-09-17 |
Family
ID=34868430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410023508XA Expired - Fee Related CN100418522C (zh) | 2004-01-08 | 2004-01-08 | 大剂量的羟基红花黄色素a或其可药用盐的制药应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100418522C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101195647B (zh) * | 2006-12-06 | 2010-08-18 | 山西华辉凯德制药有限公司 | 羟基红花黄色素a及其制备方法和应用 |
CN102614166A (zh) * | 2011-12-07 | 2012-08-01 | 中国人民解放军第四军医大学 | 一种以羟基红花黄色素a、丹参素钠制备而成的注射液及其制备方法 |
CN103127197A (zh) * | 2013-03-21 | 2013-06-05 | 悦康药业集团有限公司 | 红花黄色素注射用冻干制剂的制备方法 |
CN104230864A (zh) * | 2013-06-08 | 2014-12-24 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素a二价药用盐及其制备方法和用途 |
JP2015525232A (ja) * | 2013-02-07 | 2015-09-03 | 浙江永寧薬業股▲ふん▼有限公司 | 水酸基ベニバナ黄色素aナトリウムの製造方法及び用途 |
CN112142806A (zh) * | 2020-09-22 | 2020-12-29 | 山西德元堂药业有限公司 | 一种化合物及盐、其药物组合物及其用途 |
CN113350358A (zh) * | 2021-07-08 | 2021-09-07 | 上海市普陀区中心医院 | 远志皂苷元单用或联合羟基红花黄色素a在制备改善缺血性脑卒中后认知损害药物中的应用 |
CN113350357A (zh) * | 2020-03-05 | 2021-09-07 | 上海市普陀区中心医院 | 羟基红花黄色素a和远志皂苷元的组合物在制备治疗缺血性脑卒中的药物中的应用 |
CN114848626A (zh) * | 2022-05-09 | 2022-08-05 | 山西中医药大学 | 一种羟基红花黄色素a在调控缺血性脑卒中中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1264708A (zh) * | 1998-11-24 | 2000-08-30 | 北京市心肺血管疾病研究所 | 红花总黄色素及其制备方法和应用 |
CN1085674C (zh) * | 1998-11-24 | 2002-05-29 | 北京市心肺血管疾病研究所 | 红花总黄色素及其制备方法和应用 |
CN1245159C (zh) * | 2001-12-06 | 2006-03-15 | 长春三真实业有限公司 | 羟基红花黄色素a在制备治疗、预防心脑血管疾病方面的药物用途 |
CN1199979C (zh) * | 2001-12-29 | 2005-05-04 | 山东绿叶制药股份有限公司 | 一种治疗、预防心脑血管疾病的水溶性红花提取物及其口服制剂 |
-
2004
- 2004-01-08 CN CNB200410023508XA patent/CN100418522C/zh not_active Expired - Fee Related
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101195647B (zh) * | 2006-12-06 | 2010-08-18 | 山西华辉凯德制药有限公司 | 羟基红花黄色素a及其制备方法和应用 |
CN102614166A (zh) * | 2011-12-07 | 2012-08-01 | 中国人民解放军第四军医大学 | 一种以羟基红花黄色素a、丹参素钠制备而成的注射液及其制备方法 |
CN102614166B (zh) * | 2011-12-07 | 2014-04-09 | 中国人民解放军第四军医大学 | 一种以羟基红花黄色素a、丹参素钠制备而成的注射液 |
JP2015525232A (ja) * | 2013-02-07 | 2015-09-03 | 浙江永寧薬業股▲ふん▼有限公司 | 水酸基ベニバナ黄色素aナトリウムの製造方法及び用途 |
CN103127197A (zh) * | 2013-03-21 | 2013-06-05 | 悦康药业集团有限公司 | 红花黄色素注射用冻干制剂的制备方法 |
CN103127197B (zh) * | 2013-03-21 | 2015-02-18 | 悦康药业集团有限公司 | 红花黄色素注射用冻干制剂的制备方法 |
JP2015526398A (ja) * | 2013-06-08 | 2015-09-10 | 浙江永寧薬業股▲ふん▼有限公司 | 新たな水酸基ベニバナ黄色素ナトリウム |
CN104540811A (zh) * | 2013-06-08 | 2015-04-22 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素药用盐 |
CN104230864A (zh) * | 2013-06-08 | 2014-12-24 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素a二价药用盐及其制备方法和用途 |
EP2899186A4 (en) * | 2013-06-08 | 2016-01-06 | Zhejiang Yongning Pharmaceutical Co Ltd | NEW PHARMACEUTICAL YELLOW HYDROXYSAFFLORSALZE |
CN104540811B (zh) * | 2013-06-08 | 2017-06-06 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素药用盐 |
CN113350357A (zh) * | 2020-03-05 | 2021-09-07 | 上海市普陀区中心医院 | 羟基红花黄色素a和远志皂苷元的组合物在制备治疗缺血性脑卒中的药物中的应用 |
CN113350357B (zh) * | 2020-03-05 | 2022-11-01 | 上海市普陀区中心医院 | 羟基红花黄色素a和远志皂苷元的组合物在制备治疗缺血性脑卒中的药物中的应用 |
CN112142806A (zh) * | 2020-09-22 | 2020-12-29 | 山西德元堂药业有限公司 | 一种化合物及盐、其药物组合物及其用途 |
CN112142806B (zh) * | 2020-09-22 | 2023-03-03 | 山西德元堂药业有限公司 | 一种化合物及盐、其药物组合物及其用途 |
CN113350358A (zh) * | 2021-07-08 | 2021-09-07 | 上海市普陀区中心医院 | 远志皂苷元单用或联合羟基红花黄色素a在制备改善缺血性脑卒中后认知损害药物中的应用 |
CN114848626A (zh) * | 2022-05-09 | 2022-08-05 | 山西中医药大学 | 一种羟基红花黄色素a在调控缺血性脑卒中中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100418522C (zh) | 2008-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109906077B (zh) | 依达拉奉与(+)-2-莰醇的舌下用药物组合物 | |
CN100418522C (zh) | 大剂量的羟基红花黄色素a或其可药用盐的制药应用 | |
CN1689575A (zh) | 拟人参皂苷元(Ocotillol)在制备治疗或预防心脑血管疾病的药物中的应用 | |
CN1269498C (zh) | 一种具有解热作用的中药组合物的质量控制方法 | |
CN1876045A (zh) | 一种中药组合物制剂及其制备方法和质量控制方法 | |
CN1060344C (zh) | 治疗缺血性脑血管、心血管的药物制剂 | |
CN1686464A (zh) | 一种紫金龙注射制剂及其制备方法 | |
CN1244403A (zh) | 一种参麦等渗注射液的制备方法 | |
CN1772020A (zh) | 毛冬青冻干粉针剂及其制备方法 | |
CN1359682A (zh) | 灯盏花素磷脂复合物及其制备方法 | |
CN1234399C (zh) | 一种注射用脉络宁冻干粉的制备方法 | |
CN1785988A (zh) | 一种富含红花黄色素b的红花黄色素、制备方法和用途 | |
CN1686111A (zh) | 注射用银杏内酯针剂及其制备方法 | |
CN1817356A (zh) | 治疗心脑血管疾病的丹红注射制剂的制备方法 | |
CN1053817C (zh) | 刺五加提取物及其生产工艺以及含有该提取物的注射液和冻干粉针剂 | |
CN1799612A (zh) | 去感热注射剂新的给药途径、制备工艺、新的适应症 | |
CN1429830A (zh) | 一种治疗、预防心脑血管疾病的水溶性红花提取物及其口服制剂 | |
CN1520859A (zh) | 治疗心脑血管病的丹红注射液 | |
CN1923803A (zh) | 一种迷迭香酸精氨酸盐、制备方法、药物组合物及其用途 | |
CN1989974A (zh) | 一种治疗脑中风及后遗症的冻干粉针剂及其制备方法 | |
CN107998117B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 | |
CN100341514C (zh) | 一种防治脑梗塞的药物 | |
CN1830461A (zh) | 一种红花注射液及其制备方法 | |
CN1806795A (zh) | 一种由灯盏花素和冰片组成的复方注射制剂及其制备方法 | |
CN1660284A (zh) | 一种治疗心脑血管疾病的三七和红花复方制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20051014 Address after: No. 6 Erlang Road, Yiyuan County, Shandong, Zibo Applicant after: Shandong Ruiyang Pharmaceutical Co., Ltd. Address before: No. 9, Po Yuen Road, Laishan District, Yantai, Shandong Applicant before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: RUIYANG PHARMACY CO., LTD. Free format text: FORMER NAME OR ADDRESS: SHANGDONG RUIYANG PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: No. 6 Erlang Road, Yiyuan County, Shandong, Zibo Patentee after: Reyoung Pharmaceutical Co., Ltd. Address before: No. 6 Erlang Road, Yiyuan County, Shandong, Zibo Patentee before: Shandong Ruiyang Pharmaceutical Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: High-dose hydroxy safflower yellow A or its medically-acceptable salt application for preparing medicine for cerebral apoplexy induced from being ischemic Effective date of registration: 20161027 Granted publication date: 20080917 Pledgee: Agricultural Bank of China, Limited by Share Ltd, Yiyuan county subbranch Pledgor: Reyoung Pharmaceutical Co., Ltd. Registration number: 2016990000912 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080917 Termination date: 20200108 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201228 Granted publication date: 20080917 Pledgee: Agricultural Bank of China Limited by Share Ltd. Yiyuan county subbranch Pledgor: REYOUNG PHARMACEUTICAL Co.,Ltd. Registration number: 2016990000912 |